Lipocine (LPCN) Price & Analysis

Compare

896 Followers

LPCN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.68 - $6.17

Previous CloseN/A

Volume16.76K

Average Volume (3M)37.49K

Market Cap

$16.48M

Enterprise Value-$1.02M

Total Cash (Recent Filing)$17.94M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)650.6

Beta1.10

Next Earnings

Nov 05, 2025

EPS Estimate

-0.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding5,350,356

10 Day Avg. Volume40,326

30 Day Avg. Volume37,488

Financial Highlights & Ratios

PEG Ratio-31.18

Price to Book (P/B)1.24

Price to Sales (P/S)2.33

P/FCF Ratio-19.87

Enterprise Value/Market Cap-0.06

Enterprise Value/Revenue-0.24

Enterprise Value/Gross Profit0.54

Enterprise Value/Ebitda0.33

Forecast

1Y Price Target

$8.00

Price Target Upside159.74% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Efficacy And SafetyLPCN 1154 further improves the efficacy and safety profile compared to zuranolone with rapid onset of action and high remission rate.

Market PotentialLPCN 1154 could potentially become the best-in-class neuroactive steroid to satisfy the unmet needs in PPD, which affects approximately 600,000 women in the U.S. annually.

Regulatory ProgressPotential regulatory approval and commercialization of TLANDO in Canada could help drive Lipocine’s topline revenue.

Bears Say

Clinical Trials RiskRisks include, but are not limited to: failure of LPCN 1154 in clinical trials and failure to obtain regulatory approval.

Commercial ChallengesRisks include failure of LPCN 1154 in clinical trials and failure to achieve commercial success due to reimbursement, penetration rate, and/or competition.

Lipocine News

Lipocine reports Q2 EPS (41c) vs. (57c) last year

Reports Q2 revenue $622.85M vs. $89.57M last year. As of June 30, 2025, Lipocine (LPCN) had $17.9M of...

3d ago

LPCN

Lipocine Inc. Reports Q2 2025 Financial Results

Lipocine Inc ( ($LPCN) ) has released its Q2 earnings. Here is a breakdown of the information Lipocine...

2d ago

LPCN

Buy Rating for Lipocine: LPCN 1154’s Promising Potential in Postpartum Depression Treatment

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Lipocine and keeping the price target at...

28d ago

LPCN

Lipocine Hosts Virtual Event on LPCN 1154

The latest update is out from Lipocine ( ($LPCN) ). On July 9, 2025, Lipocine hosted a virtual...

29d ago

LPCN

Lipocine Updates Corporate Presentation for Investors

Lipocine ( ($LPCN) ) just unveiled an announcement. Lipocine has updated its corporate presentation used for meetings with...

1M ago

LPCN

Positive Outlook on Lipocine: Promising Clinical Developments and Commercial Prospects Support Buy Rating

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Lipocine (LPCN – Research Report). The...

1M ago

LPCN

Lipocine Begins Phase 3 Trial for LPCN 1154

An announcement from Lipocine ( ($LPCN) ) is now available. On June 26, 2025, Lipocine Inc. announced the...

1M ago

LPCN

Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154

Lipocine (LPCN) announced that the first patient has been dosed in its pivotal Phase 3 clinical trial of...

1M ago

LPCN

Lipocine to Host R&D Event on July 9

Lipocine ( ($LPCN) ) has provided an update. Lipocine Inc. announced it will host a virtual R&D investor...

2M ago

LPCN

Lipocine’s Growth Potential Bolstered by TLANDO’s Canadian Market Entry and Phase 3 Trial for LPCN 1154

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Lipocine (LPCN – Research Report), retaining the...

2M ago

LPCN

Lipocine announces filing of NDA for TLANDO in Canada

Lipocine (LPCN) announced that its licensing partner, Verity Pharma, filed a New Drug Submission, NDS, for TLANDO in...

2M ago

LPCN

Lipocine’s Partner Files New Drug Submission in Canada

Lipocine ( ($LPCN) ) has shared an update. On June 9, 2025, Lipocine announced that its licensing partner,...

2M ago

LPCN

Lipocine Approves Key Proposals at Shareholder Meeting

Lipocine ( ($LPCN) ) has issued an update. On June 4, 2025, Lipocine Inc. held its annual general...

2M ago

LPCN

Lipocine assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen assumed coverage of Lipocine (LPCN) with a Buy rating and $8 price target...

2M ago

LPCN

LPCN FAQ

What was Lipocine Inc’s price range in the past 12 months?

Lipocine Inc lowest stock price was $2.68 and its highest was $6.17 in the past 12 months.

What is Lipocine Inc’s market cap?

Lipocine Inc’s market cap is $16.48M.

When is Lipocine Inc’s upcoming earnings report date?

Lipocine Inc’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.

How were Lipocine Inc’s earnings last quarter?

Lipocine Inc released its earnings results on Aug 05, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$0.01.

Is Lipocine Inc overvalued?

According to Wall Street analysts Lipocine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lipocine Inc pay dividends?

Lipocine Inc does not currently pay dividends.

What is Lipocine Inc’s EPS estimate?

Lipocine Inc’s EPS estimate is -0.51.

How many shares outstanding does Lipocine Inc have?

Lipocine Inc has 5,350,356 shares outstanding.

What happened to Lipocine Inc’s price movement after its last earnings report?

Lipocine Inc reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went down -1.597%.

Which hedge fund is a major shareholder of Lipocine Inc?

Currently, no hedge funds are holding shares in LPCN

Company Description

Lipocine Inc

Lipocine Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for metabolic and endocrine disorders. The company specializes in drug delivery technologies, particularly those that utilize its proprietary Lip'ral™ platform, which enhances the absorption and bioavailability of orally administered drugs. Lipocine's core products include LPCN 1021, a testosterone replacement therapy, and LPCN 1144, aimed at treating nonalcoholic steatohepatitis (NASH).

Lipocine (LPCN) Earnings & Revenues

Historic Earnings Reports

LPCN Stock 12 Month Forecast

Average Price Target

$8.00

▲(159.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","22":"$22","6.25":"$6.25","11.5":"$11.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.25,11.5,16.75,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.19,3.56,3.93,4.3,4.67,5.04,5.41,5.78,6.15,6.5200000000000005,6.890000000000001,7.26,7.630000000000001,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.19,3.56,3.93,4.3,4.67,5.04,5.41,5.78,6.15,6.5200000000000005,6.890000000000001,7.26,7.630000000000001,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.19,3.56,3.93,4.3,4.67,5.04,5.41,5.78,6.15,6.5200000000000005,6.890000000000001,7.26,7.630000000000001,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.59,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.38,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1688169600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.67,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >